Download this poster presented at ESACT 2022 about how we developed two targeted integration systems that express high levels of recombinant protein in CHO cells…
Read the article on our continuous manufacturing technologies used in our cGMP manufacturing facility J.POD.
Watch the recorded webinar on AI-driven antibody discovery as part of Evotec’s Innovation Week held in December 2021. A week full of live sessions with…
Read the article on our cGMP manufacturing facility J.POD in the June edition of BioProcess Int.
Download this poster presented at the 2022 International Conference on Antiviral Research entitled AI-Derived Antibodies are novel, diverse and pharmacologically active against multiple SARS-CoV-2 strains
Download this poster presented at the 2022 ACS spring conference entitled High throughput optimization of chromatography steps for viral clearance using retrovirus-like particles (RVLPs)
Watch the recorded webinar on AI-driven antibody discovery as part of Evotec’s Innovation Week held in December 2021. A week full of live sessions with…
Just – Evotec Biologics, launched a long-term tech partnership with Sandoz for the immediate development and manufacturing of biosimilars
EIB has granted Evotec an unsecured Loan facility of € 150 m to support the company’s R&D activities, equity investments and the building of the…
Just–Evotec Biologics has been awarded for its flexible cGMP biomanufacturing plant J.POD. The CPhI Award for Manufacturing Technology and Equipment honors innovation in technologies, products,…
Just–Evotec Biologics will support the DOD with rapid, cost-efficient development of safe, efficacious anti-plague mabs. Evotec will provide pre-clinical and clinical trial services.
J.POD® Toulouse, France (EU) Brings a disruptive, flexibly scalable biologics manufacturing technology to the region. The manufacturing facility is expected to be operational in H2…